Market Place
Sourcing Support
Avacta Reports Pipeline Advances At EORTC-NCI-AACR Symposium
24 Oct 2024 //
GLOBENEWSWIRE
Avacta And Tempus Collaborate To Advance AI-Driven Drug Development
21 Oct 2024 //
GLOBENEWSWIRE
Avacta Expands Pipeline With Two Assets From pre|CISION® Platform
17 Oct 2024 //
GLOBENEWSWIRE
Avacta Group Strengthens Team With Michelle Morrow As CSO
15 Oct 2024 //
GLOBENEWSWIRE
Avacta Group Appoints Michelle Morrow As Chief Scientific
15 Oct 2024 //
GLOBENEWSWIRE
Avacta To Unveil Pipeline Expansion At 2024 EORTC-NCI-AACR Symposium
10 Oct 2024 //
GLOBENEWSWIRE
Avacta Reports AVA6000 Phase 1 Data At ESMO With Durable Responses
14 Sep 2024 //
GLOBENEWSWIRE
Avacta To Present AVA6000 Data At ESMO Congress
08 Sep 2024 //
GLOBENEWSWIRE
Avacta Appoints Darlene Deptula-Hicks As Non-Executive Board Director
08 Jul 2024 //
GLOBENEWSWIRE
Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update
05 Apr 2024 //
GLOBENEWSWIRE
Updated Results from Single-Agent Phase 1 of Peptide Drug Conjugate, AVA6000
05 Mar 2024 //
GLOBENEWSWIRE
Appointment of Chief Business Officer
19 Dec 2023 //
GLOBENEWSWIRE
ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data
13 Dec 2023 //
GLOBENEWSWIRE
Avacta to present promising new data from Affimer
05 Oct 2023 //
GLOBENEWSWIRE
Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000
21 Jun 2023 //
BUSINESSWIRE
Avacta enrolls fifth patient in cohort of AVA6000 phase Ia dose escalation study
08 Apr 2023 //
PHARMABIZ
Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Study
06 Apr 2023 //
BUSINESSWIRE
Avacta Announces First Patient Dosed in Cohort of AVA6000 PhIa Escalation Study
05 Apr 2023 //
BUSINESSWIRE
Avacta Appoints Karen Harrison as Chief Operating Officer
28 Mar 2023 //
BUSINESSWIRE
Avacta Names Karen Harrison COO for Therapeutics Division
28 Mar 2023 //
CONTRACT PHARMA
Avacta to Present Pre-Clinical Data on AVA3996 at Annual Meeting
27 Mar 2023 //
BUSINESSWIRE
Avacta Announces Completion of Fourth Dose Escalation in AVA6000 Phase 1 Study
17 Jan 2023 //
BUSINESSWIRE
US FDA grants Orphan Drug status to Avacta’s drug for soft tissue sarcoma
06 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
Avacta Announces AVA6000 Receives Orphan Drug Designation From the US FDA
05 Sep 2022 //
BUSINESSWIRE
Avacta announces clinical study of AVA6000
01 Sep 2022 //
PHARMATIMES
Avacta Announces PI Clinical Study of AVA6000 to Advance to the Fourth Cohort
01 Sep 2022 //
BUSINESSWIRE
Avacta`s doxorubicin prodrug clears another early safety test
05 Jul 2022 //
FIERCEPHARMA
LG Chem Renews License Triggering Payment to Avacta
30 Jun 2022 //
BUSINESSWIRE
Avacta announces escalation in clinical study of AVA6000
29 Jun 2022 //
PHARMATIMES
Avacta Announces Second Dose Escalation in PI Study of AVA6000 Pro-doxorubicin
29 Jun 2022 //
BUSINESSWIRE
Avacta Relocates Therapeutics Division to Scale Space
11 May 2022 //
CONTRACTPHARMA
Avacta Announces AffyXell Joint Venture Milestone and Increased Equity Stake
13 Apr 2022 //
BUSINESSWIRE
Avacta Appoints Dr Christina Coughlin as Non-Executive Director
21 Mar 2022 //
BUSINESSWIRE
Avacta Announces Dose Escalation in Phase I Study of AVA6000 Pro-doxorubicin
03 Feb 2022 //
BUSINESSWIRE
Avacta Selects Second pre|CISION™ Pro-drug Candidate for Development
18 Jan 2022 //
BUSINESSWIRE
Avacta pauses sales of COVID-19 antigen test to improve Omicron sensitivity
10 Jan 2022 //
REUTERS
Avacta lateral flow test receives CE mark for consumer self-testing
22 Dec 2021 //
PHARMAFILE
Avacta Announces AffiDX SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark
22 Dec 2021 //
BUSINESSWIRE
Avacta Announces AffiDx SARS-CoV-2 Antigen Lateral Flow Test
15 Dec 2021 //
BUSINESSWIRE
Avacta Announces FDA Approval of its I (IND) Application for AVA6000
29 Nov 2021 //
BUSINESSWIRE
Avacta Group and LG Chem Partnership Achieves Pre-clinical Development Milestone
29 Sep 2021 //
BUSINESSWIRE
Avacta appoints Scientific Advisory Board of its Therapeutics Division
06 Sep 2021 //
FIRSTWORD PHARMA
Appointment of Fiona McLaughlin as CSO of Avacta’s Therapeutics Division
03 Sep 2021 //
MANUFACTURING CHEMIST
Avacta begins patient dosing in phase I AVA6000 trial of doxorubicin
11 Aug 2021 //
PHARMABIZ
Avacta’s Diagnostic Division Achieves ISO 13485 Certification
14 Jul 2021 //
BUSINESS WIRE
Avacta’s Diagnostic Division Achieves ISO 13485 Certification
14 Jul 2021 //
BUSINESS WIRE
Avacta inks agreement with Calibre Scientific
22 Jun 2021 //
PHARMABIZ
Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Agreement
21 Jun 2021 //
BUSINESSWIRE
Avacta Registers its AffiDX SARS-CoV-2 Antigen Lateral Flow Test Europe
11 Jun 2021 //
BUSINESSWIRE
Avacta Registers its AffiDX SARS-CoV-2 Antigen Lateral Flow Test Europe
11 Jun 2021 //
BUSINESSWIRE
MHRA Confirms Registration of AffiDX COVID Antigen Lateral Flow Test
07 Jun 2021 //
BUSINESSWIRE
Avacta receives clinical validation of AffiDX SARS-CoV-2 antigen lateral
22 Apr 2021 //
PHARMABIZ
Avacta receives clinical validation of AffiDX SARS-CoV-2 antigen lateral test
21 Apr 2021 //
PHARMABIZ
Avacta Receives Clinical Validation of AffiDX SARS-CoV-2 Antigen Lateral Flow
19 Apr 2021 //
BUSINESSWIRE
Avacta’s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants
08 Mar 2021 //
BUSINESSWIRE
Avacta gets MHRA green-light to start phase I trial for ‘pro-drug’ chemotherapy
18 Feb 2021 //
PHARMATIMES
Avacta Announces Phase 1 Clinical Trial Authorisation (CTA) for AVA6000
18 Feb 2021 //
BUSINESSWIRE
Avacta Announces Phase 1 Clinical Trial Authorisation (CTA) for AVA6000 MHRA
17 Feb 2021 //
BUSINESSWIRE
Avacta Announces Results of Initial Evaluation of SARS-CoV-2 Lateral
15 Feb 2021 //
BUSINESSWIRE
Avacta Announces License Agreement With POINT Biopharma Inc.
07 Jan 2021 //
BUSINESSWIRE
